On the 22nd of July, Biovica had fruitful meeting with the FDA regarding Supplement II that discusses the approach for clinical validation of DiviTum.

Next step is to document the conclusions from the meeting, which the FDA will review and signoff. This process will take a maximum of 45 days.

Thereafter, Supplement II will be completed, and the result can be concluded and communicated.